Search - tctmd.com

Displaying 601 - 620 of 1583

Sort: Relevancy | Date

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

News Features

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

January 13, 2022

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

News Daily News

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

January 11, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

Statins No Benefit to ICU-Admitted COVID-19 Patients: INSPIRATION-S

News Daily News

Statins No Benefit to ICU-Admitted COVID-19 Patients: INSPIRATION-S

January 07, 2022

Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study

News Daily News

Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study

Yael L. Maxwell

January 03, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

Black Patients With Chest Pain Differ From Whites, but Risks Are Similar

News Daily News

Black Patients With Chest Pain Differ From Whites, but Risks Are Similar

Michael O'Riordan

December 23, 2021

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions

News Daily News

Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions

December 17, 2021

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

News Daily News

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

Yael L. Maxwell

December 14, 2021

British Medical Groups Express Concern About Inclisiran Rollout

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Another Study Links Stopping Statins to MACE in the Elderly

News Daily News

Another Study Links Stopping Statins to MACE in the Elderly

December 03, 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.